Published in Physiological Reviews, this Wellcome Trustβfunded review by Juliet E. Compston (University of Cambridge) synthesizes ~395 references spanning bone cell biology, lifetime bone-mass trajectories, estrogen/progesterone/androgen mechanisms, and SERMs into a single authoritative narrative .
The review's mechanistic core: estrogen deficiency raises activation frequency of bone remodeling units and produces remodeling imbalance, largely via cytokine-mediated effects β estrogen suppresses IL-1, IL-6, and TNF-Ξ±, increases osteoprotegerin (OPG), and promotes osteoclast apoptosis via TGF-Ξ². Histomorphometric evidence from GnRH-analogβinduced estrogen withdrawal in premenopausal women showed rapid trabecular disruption within 6 months, supporting a transient increase in osteoclastic resorption depth, not just elevated turnover .
Schematic reconstruction of the review's Fig. 6 concept β the qualitative pattern (peak in third decade, menopause acceleration in women, lifelong loss in both sexes) β not observed patient data.
Limitations: reliance on cross-sectional histomorphometry with small samples and large measurement variance (the author self-cites this); ovariectomized-rat models imperfectly translate; progesterone/bone evidence was genuinely conflicting (norethisterone preserved, norgestrel lost metacarpal BMD). Missing: no RCT-level fracture data for estrogen itself β the review openly states evidence for hip/vertebral fracture protection was 'almost exclusively from observational studies.' This is the review's key epistemic vulnerability, correctly framed at the time but later resolved against unopposed HRT for chronic disease prevention.
Confidence in the mechanistic synthesis: high (strong, convergent animal + human cellular + clinical-genetic evidence). What would change this conclusion: demonstration that RANKL/OPG signaling is dispensable for estrogen's antiresorptive effect in humans, or that cytokine-mediated pathways do not explain postmenopausal bone loss β the 2001 review predates definitive RANKL-pathway pharmacology but correctly anticipated its centrality.
Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.